New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome

Ahmed Abdal Dayem1, Kwonwoo Song1, Soobin Lee1, Aram Kim2,* & Ssang-Goo Cho1,*
1Department of Stem Cell & Regenerative Biotechnology and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, Seoul 05029, 2Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05029, Korea

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disorder characterized by suprapubic pain and urinary symptoms such as urgency, nocturia, and frequency. The prevalence of IC/BPS is increasing as diagnostic criteria become more comprehensive. Conventional pharmacotherapy against IC/BPS has shown suboptimal effects, and consequently, patients with end-stage IC/BPS are subjected to surgery. The novel treatment strategies should have two main functions, anti-inflammatory action and the regeneration of glycosaminoglycan and urothelium layers. Stem cell therapy has shown to have dual functions. Mesenchymal stem cells (MSCs) are a promising therapeutic option for IC/BPS, but they come with several shortcomings, such as immune activation and tumorigenicity. MSC-derived extracellular vesicles (MSC-EVs) hold numerous therapeutic cargos and are thus a viable cell-free therapeutic option. In this review, we provide a brief overview of IC/BPS pathophysiology and limitations of the MSC-based therapies. Then we provide a detailed explanation and discussion of therapeutic applications of EVs in IC/BPS as well as the possible mechanisms. We believe our review will give an insight into the strengths and drawbacks of EV-mediated IC/BPS therapy and will provide a basis for further development. [BMB Reports 2022; 55(5): 205-212]

INTRODUCTION

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating pain syndrome that presents with a wide range of symptoms including pelvic pain, urinary frequency, urgency, and cystoscopy findings, such as Hunner’s lesion or glomerulation following hydrodistension. However, its diagnosis depends on the exclusion of other overlapping disorders. The prevalence of IC/BPS was long known to be higher in females (1). However, recent reports have demonstrated a higher prevalence in males (2, 3). Although no consensus exists on the actual pathophysiology of IC/BPS, numerous theories have emerged including mast cell infiltration, inflammation, glycosaminoglycan (GAG) layer/urothelial dysfunction, and autoimmune dysregulation (4, 5).

Urothelium, a special form of epithelial tissue that lines the urinary tract walls, including the proximal urethra and urinary bladder, serves as a vital barrier against pathogens, toxins, and wastes (6, 7). The urothelium, which is made up of uroplakins (UPs) complexes, forms the urine-blood barrier and is supported by a thick pseudostratified transitional epithelium (multi-layered) and an asymmetric and fully differentiated superficial membrane (umbrella) (8-10). UPs are categorized into four subtypes: UP1a, UP1b, UP2, and UP3, which are implicated in the urothelium’s permeability. These proteins coalesce together to form crystalline plaques on the bladder lumen’s surface (10, 11). Proliferation or hyperplasia is a defensive reaction to any damage to the urothelium to rebuild the urine-blood barrier (12, 13). The main obstacles to bladder tissue regeneration are the scarcity of adequate tissue sources and senescence-associated primary cultures of bladder cells for several passages (14). For example, some trials using gastrointestinal tract-derived tissue for bladder regeneration showed inefficiency due to tumor formation, recurrent infection, metabolic abnormalities, and stone formation (15). Through the present comprehensive review article, we want to report risk and benefit of stem cell therapy for IC/BPS. In addition, we would introduce new approach with extracellular vesicles (EVs) from stem cell in order to push the limit of the stem cell therapy.

KEYWORDS: Bladder, Exosome, Extracellular vesicles, IC/BPS, Stem cell

CONTENTS

Conventional treatment for IC/BPS
There are several drugs and surgical methods which are recommended for IC/BPS therapy by global societies, such as the American Urological Association (AUA), the European Society for the Study of IC (ESSIC), and the Society of Interstitial Cystitis of Japan (SICJ) (16). Unfortunately, the current conventional drugs and
alternative surgical interventions do not guarantee complete recovery and are associated with harmful side effects (16, 17).

Because of its chronic nature and high prevalence, bladder dysfunction is an attractive target for stem cell therapy. Numerous preclinical trials for bladder dysfunction, such as detrusor underactivity, stress urinary incontinence, overactive bladder, and IC/BPS, have been established, although clinical investigations in patients are still sparse (18).

Urgent need of new therapeutic strategy

Stem cell-based bladder dysfunction therapy includes several mechanisms, such as anti-inflammation, anti-fibrosis, urothelium regeneration, anti-oxidant, anti-apoptosis, and modulation of specific signaling pathways including Wnt and AKT/mTOR pathways (19). Therefore, stem cell-based therapy has garnered attention as a robust alternative option.

Mesenchymal stem cells (MSCs) have a proven record of therapeutic efficacy in human clinical trials and have been effective in a wide range of pre-clinical studies of tissue regeneration in various immunologic and degenerative diseases (20-22). MSCs secrete paracrine factors, which are the key mediators of MSC-associated therapeutic activities. Most, if not all, of the MSCs’ paracrine activities, are mediated by EVs, which are 50-1000 nm in diameter and secreted by all cell types (23, 24). EVs pass through biological barriers such as the blood-brain barrier (25) and synovial membranes (26). It is evidenced that EVs are carriers of the exogenous RNAs, such as siRNA (27), miRNA (28), and modified miRNAs (29), which could be functional molecules in vitro and in vivo. In addition, previous reports demonstrated the immunostimulatory or immunosuppressive capacities of EVs based on their target and cellular source (30). The immunomodulatory capacities of EVs could be beneficial for the treatment of inflammatory, autoimmune, and hypersensitivity diseases (31). Small EVs (sEVs), of 50 to 200 nm in diameter, isolated from MSC culture supernatants that are maintained under various culture conditions, have proved to be therapeutically effective in various preclinical models (23, 32).

Pathophysiology of IC/BPS

The aetiology of IC/BPS is perplexing (33). Nevertheless, numerous hypotheses endeavor to explain IC/BPS pathogenicity. Bladder epithelial damage, mast cell activation, neuroinflammation, suppression of tight junction protein, afferent nerve plasticity, infection, abnormal urothelial signaling, destruction of the superficial urothelial GAG layer, and psychological factors have been reported as the etiological factors that lead to IC/BPS as illustrated in Fig. 1 (16, 34, 35). A commonly acknowledged postulation of IC/BPS pathophysiology proposes that the chronic inflammatory state is induced by early damage or defect in the mucosal membrane of the bladder. Urothelium, a unique type of epithelium, is composed of polysaccharides (chondroitin sulfate and hyaluronic acid) in its outer layers and glycoproteins in the deeper layers (36). The injured urothelium is the main culprit for the impaired barrier function, which allows urine solutes, such as potassium ions, to seep into the suburothelium, leading to neuronal and muscle cells depolarization and inflammation-related damage, urgency, and pain (37, 38).

The bladder pain is aggravating, especially, during the bladder filling process. Besides its barrier function, urothelium is also implicated in sensory transduction through sensing physiological and chemical signals in the bladder wall and releasing signaling molecules (39). Urothelium-mediated signal transduction is not fully characterized; however, urothelial cells can produce substances P, acetylcholine, and ATP, which are involved in the activation of the bladder afferent neurons (40).

Chronic inflammation possibly plays a key role in IC/BPS pathogenesis. In bladder biopsies of some patients with bladder pain, mast cells, leucocytes, and lymphocytes were found infiltrating the bladder wall and suburothelial layers, along with increased vasculature and thickening of the bladder wall. The clinical observations demonstrated subsequent chronic pain in patients with frequent reports of urinary tract infections (UTIs). UTIs are among the exacerbating factors of IC/BPS that commence at an early age and progress to IC/BPS in adulthood (41). In IC/BPS patients, the proliferating mast cells in the bladder wall have been linked to inflammation, allergic responses, and bladder hypersensitization (42, 43).

Of note, a link has been shown between the incidence of clinical IC/BPS and autoimmune diseases (44). Autoantibodies, which are involved in the autoimmunity mechanism, showed an adverse action on the bladder urothelium, connective tissues, and smooth muscles (44). Further, a nationwide study recently reported IC/BPS in patients with primary Sjögren’s syndrome (45). Taken together, there is a strong link between autoimmune disorders and IC/BPS pathogenicity, as evidenced by the chronic inflammation and the presence of autoantibodies.

Fig. 1. IC/BPS Pathophysiology. GAG, glycosaminoglycan; UTI, urinary tract infections; NGF, nerve growth factor; IL-6, interleukin-6; CNS, Central nervous system. The figure is reproduced from the article by Dayem et al. 2020 (16). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CCBY) license (http://creativecommons.org/licenses/by/4.0/).
Limitations of stem cell therapy

Before discussing stem cell therapy limitations, we first need to briefly address the beneficial effects of stem cells in the treatment of various diseases, especially IC/BPS. Basically, MSC-based therapies are attributed to their intertwined roles including suppressing inflammation by releasing cytokines, supporting healing by expressing growth factors, altering host immune responses by secreting immunomodulatory factors, augmenting responses from endogenous repair cells, and acting as mature functional cells such as bone cells (46). Stem cell-mediated IC/BPS therapy is ascribed to various mechanisms, including their direct differentiation into the main bladder cells, including urothelium and smooth muscles (SMCs), their transplantation via several routes, and the activation of the vital signaling pathways that are involved in bladder regeneration, such as mitogen activated protein kinases, AKT, Wnt-β-catenin, and mTOR signaling pathways (16, 47-50). The possible application of stem cells in treatment of the bladder diseases at the preclinical level is also proved (18). However, Clinicaltrials.gov currently shows no ongoing stem cell treatment clinical trials in IC/BPS (18). On the other hand, the main concern over stem cell therapy is the lack of safety proof. It is difficult to implant foreign living cells into a sophisticated structure like the human body. Due to the vision loss in patients with macular degeneration, an age-related eye condition, after the injection of autologous stem cells at a U.S. clinic (51), there has been a growing concern over the safety of unproven stem cell therapies are used. The risk of post-transplantation tumorgenicity is associated with the donor’s age, growth modulation by the recipient tissues (52), and the dysfunction of the patient immune system due to long-term chemotherapy (53). Of note, long-term in vitro culture of MSCs could lead to unfavorable consequences, such as chromosomal abnormalities, senescence, and genetic instabilities, which negatively influence the engraftment (52, 54). Moreover, investigations in rodents and dogs demonstrated that intravenously injected MSCs are trapped in the pulmonary capillaries and large populations of MSCs are largely cleared, but some get through to the damaged target tissue (55-58). In addition, stem cell engraftment led to immune reaction-associated stress that resulted in unfavorable outcomes, such as cellular necrosis and differentiation anomalies (59).

Specifically, stem cell therapy holds numerous limitations and challenges that hinder its clinical application in bladder disease therapies, such as the controversies over the transplantation route and the dose of the cells, the undefined mechanism of action of several stem cell-mediated bladder disease therapies, and the in vitro IC/BPS models used for verification of stem cell effects lack the reproducibility and needs further careful authentications (16, 60).

Furthermore, when stem cells are introduced to target cells, the therapeutic effectiveness of MSCs may not correspond with engraftment, differentiation, or cell fusion (61). Overall, MSCs therapeutic actions are mediated via the paracrine effect, which is involved in tissue repair, and not replacement-based therapy (62). In this prime, numerous studies demonstrated that MSC-conditioned culture medium produced therapeutic effects similar to cell delivery in rodent models of various disease models (63, 64), which has been supported by genomics data showing that MSCs secrete a huge array of bioactive proteins (65, 66).

Overcoming the hurdles with stem cell-derived EVs

MSCs application in urologic regenerative medicine has been widely studied due to their multilineage differentiation capacity (67, 68). However, the potential MSCs tissue regeneration mechanism is by their paracrine action via the released soluble factors including growth factors, cytokines, and chemokines rather than MSC differentiation and structural interaction with host tissue (69, 70). The paracrine effect is dependent on the transfer of proteins, bioactive lipids, and genetic material such as miRNA, miRNAs, and other non-coding RNA. The paracrine impact of stem cells is also mediated via secreted EVs (71). MSCs can release a wide spectrum of soluble factors such as secretomes into the culture medium, which are less immunogenic and tumorigenic (72, 73). MSC paracrine activity could be classified into various activities, such as anti-apoptotic, anti-inflammatory, angiogenic, immunosuppressive, and immunomodulating impacts (74).

The specific compositions of MSC-derived EVs (MSC-EVs) differ according to tissue source and in vitro cell stimulation approach (72); EVs isolation procedures include ultracentrifugation, filtration, immunoaffinity, precipitation, size exclusion, and micro-fluidic devices (75, 76). The basic criteria for EVs isolation and characterization are based on the recommendations by Minimal information for studies of extracellular vesicles 2018 (MISEV2018) (77). However, the recent EVs isolation techniques are limited by lack of reproducibility and variation in the quality of the EVs produced, and therefore need further considerations (78). Broadly, EVs could be categorized as “exosomes” or “microvesicles” (24). The term “exosome” commonly refers to a specific class of EVs formed by the endosomal system (79), which vary from the “ectosomes” (microvesicles and microparticles) that emerge from the plasma membrane (80) or other similarly sized EVs with an undefined biogenesis pathway (81). “Small” in the term sEVs indicates a population range of approximately 50-200 nm in diameter. The production of sEVs is currently thought to be one of the mediators of MSC therapeutic properties (23). In numerous in vitro functional assays and relevant pre-clinical disease models, sEVs derived from in vitro MSC cells have been reported to have therapeutic activities that imitate those of MSCs (82, 83). Furthermore, MSC-EVs convey a large amount of verified therapeutic agents into target cells, such as nucleic acids, proteins, miRNA, and lipids, to modulate numerous biological functions (84). MSC-EV-associated tissue regeneration is majorly attributed to the MSC-EVs capacity to enhance the proliferation process and suppression of the apoptotic changes (85, 86). The prominent role of MSC-EVs in maintaining the immune hemostasis is attributed to the modulation of immune cell fate and inhibition of uncontrolled inflammation (85, 87). One of the key mechanisms of MSC-EVs in tissue regeneration is stimulation of the angiogenesis via activation of various signaling pathways (88, 89). The MSC-EVs...
Extracellular vesicles from stem cells for intestinal cystitis/bladder pain syndrome
Ahmed Abdal Dayem, et al.

Fig. 2. MSC-EVs mechanisms in IC/BPS therapy. A schematic diagram summarizing MSC-EV separation methods and their potential modes of action in IC/BPS therapy. Parts of this figure were created using Servier Medical Art (https://smart.servier.com), licensed under a Creative Commons Attribution 3.0. AKT: serine/threonine kinase, mTOR: mechanistic target of rapamycin kinase, TGF-β: transforming growth factor-β, IL: interleukin, αSMA: α Smooth muscle actin.

Urinary bladder wall diseases therapeutic activities are mediated via the bladder tissues regeneration and suppression of inflammation, which helps to prevent disease development and recurrence (73). Besides the possible effects of the purified EVs in the treatment of bladder diseases, we will also explain examples of the roles of stem cell conditioned medium (CM) or co-culture platforms in bladder disease therapy that represent the paracrine action of stem cells in which EVs are potently involved. In 2014, Adamowicz et al. demonstrated the regenerative capacity of MSC-derived conditioned media (MSC-CM) in the bladder wall when administered intravesically in IC patients, which was attributed to its high content of cytokines, growth, and trophic factors that possess immunomodulatory, anti-inflammatory, and angiogenic activities (90). In 2018, Xie et al. demonstrated the potency of umbilical cord-derived mesenchymal stem cells (UC-MSCs) to alleviate the inflammatory-associated changes, enhance the proliferation, and block the apoptosis when co-cultured within human urothelial cells, SV-HUC-1 cells that were pretreated with TNF-α (91). Interestingly, the application of siRNA targeting EGF in the UC-MSCs abolished the anti-inflammatory activity of UC-MSCs when co-cultured with TNF-α-exposed SV-HUC-1 cells. The authors showed that increased AKT and mTOR, as well as significant decrease in the protein expression level of the cleaved caspase-3, are involved in the therapeutic activity of UC-MSCs against the in vitro interstitial cystitis model using TNF-α-treated SV-HUC-1 cells (91).

Hypoxia is implicated in the activation of the inflammatory events and the consequent fibrosis of the bladder smooth muscles (92). In this regard, a study by Wiafe and colleagues detected the in vitro upregulation of hypoxia-associated genes, TNF-α, IL-1β, IL-6, HIF3α, VEGF, TGF-β1, and αSMA, in 3% oxygen tension-exposed bladder SMCs and then tested the effects of direct and indirect co-culture with bone marrow-derived MSCs (BM-MSCs) in reducing hypoxia-related changes (93). Direct co-culture is cell-to-cell interaction, whereas indirect co-culture (based on trans-well system) is cell-to-cell interaction independent. Interestingly, both co-culture methods led to a significant down-regulation of TGF-β1 and IL-6, which are associated with fibrosis and pro-inflammatory, respectively. Moreover, the significant increase in the expression level of the potent anti-fibrotic cytokine, IL-10, and the marked decrease in the expression level of αSMA, collagen I and III transcripts, and the total collagen proteins were demonstrated upon co-culture with BM-MSCs. Taken together, MSC-EVs were evidenced to be effective IC therapies via several mechanisms, including delivery of therapeutic miRNA and growth factors, anti-inflammation, anti-fibrosis, and modulation of key signaling pathways (Fig. 2).

In 2017, Lv et al. affirmed the cross-link between miR-214 inhibition and the enhancement of epithelial-mesenchymal transition that leads to fibrosis of the bladder wall and subsequent interstitial cystitis in postmenopausal women, which is mediated via the upregulation of Mitofusin 2 (Mfn2) (94). Accordingly, another study confirmed the protective capacity of exosomes derived from miR-214-enriched BM-MSC, which were cultured under hypoxic conditions against the oxidative damage in the cardiac stem cells (95). This effect is mediated via the suppression of calcium/calmodulin-dependent protein kinase II (CaMKII). Taken together, this study paves the way for revisiting the effect of calcium/calmodulin-dependent protein kinase II (CaMKII).

Various MSC-EVs showed anti-inflammatory (96), anti-fibrotic (97, 98), immunomodulatory (99) functions via modulation of a wide range of miRNAs, which need to be tested in IC/BPS therapy. In addition, there is a scarcity of studies that show the impact of stem cell derived EVs in IC/BPS therapy, which paves the way for further studies and clinical trials as well. A brief comparison between MSC and EVs in cystitis therapy is summarized in Table 1.
Table 1. Comparison of stem cell therapy and EVs therapy

| Item                        | Stem cell therapy                                                                 | EVs therapy                                                                 |
|-----------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Source                      | Primary tissues of various body organs                                             | Cultured media                                                               |
| Interstitial cystitis therapy mechanisms | - Cell replacement via their differentiation into urothelium and muscle layers     | - Delivery of therapeutic molecules (miRNA and growth factors)                |
|                             | - Migration to injured site                                                        | - Enhance proliferation                                                        |
|                             | - Anti-inflammation                                                               | - Anti-fibrosis                                                               |
|                             | - Anti-fibrosis                                                                   | - Anti-apoptosis                                                              |
|                             | - Modulation of signaling pathways                                                | - Immunomodulation                                                            |
| Pros                        | - Availability                                                                    | - Cell-free platform                                                          |
|                             | - Easily isolated and expanded                                                    | - Carrier of the cell therapeutic molecules                                    |
|                             | - Multilineage differentiation                                                    | - Easily engineered                                                           |
|                             | - Unique immunological properties                                                | - Easily stored                                                               |
|                             | - Post-transplantation tumorigenicity                                              | - Costly                                                                      |
|                             | - Donor-dependent quality                                                         | - Irreproducible and inefficient separation methods                          |
|                             | - Genetic instability and chromosomal abnormalities                               | - Heterogeneity                                                               |
|                             | - Senescence                                                                      | - EVs characterization                                                        |
|                             | - Short-term survival at the injured site                                         | - Difficulties                                                                |
|                             | - Engraftment failure                                                             | - Scarcity of EVs specific markers                                            |

CONCLUSIONS
IC/BPS is a complicated chronic illness with unclear etiology. There are a variety of IC/BPS therapeutic options and surgical interventions, however, they are associated with detrimental side effects and do not guarantee a complete recovery. MSCs have shown unique therapeutic activities and have been considered for the treatment of bladder diseases. However, stem cells engraftments for bladder tissue regeneration face major challenges such as immune reaction, low survival rate, and tumorigenicity, which limit their clinical application. To overcome these constraints, numerous scientific works have demonstrated the efficiency of paracrine mechanisms of MSCs in the treatment of a wide range of diseases, which is represented in the secretion of a diverse range of growth factors, miRNAs, proteins, cytokines, and chemokines. EV secretion is considered the main mediator of MSCs paracrine mechanism. Here, we highlighted the advantages of the application of EVs as a cell-free platform over the direct use of stem cells in cystitis therapy. We explained how EVs contribute to cystitis treatment via the enhanced proliferation, anti-inflammatory, anti-fibrotic, and immunomodulatory functions. Furthermore, we showed the role of EVs as cargos for therapeutic molecules such as miRNAs and their role in the alleviation of cystitis. However, further investigations into EVs carried by EVs in IC/BPS therapy are needed. Moreover, further in-depth comparative studies on MSCs and their EVs in IC/BPS treatment are required for the clarification of the effectiveness and efficacy of EVs over the parent MSCs before the clinical applications. We believe further improvements in separation, characterization, engineering, and efficacy evaluation of MSC-EVs are essential for deriving high quality EVs with utmost activity for IC/BPS therapy in the future.

ACKNOWLEDGEMENTS
This study was supported by a grant from the National Research Foundation (NRF), funded by the Ministry of Education (NRF-2019R111A2A01063045) and the Korean Government (Ministry of Education, Science, and Technology) under Grant numbers 2019M3A9H1030682 and 2020R1F1A106709912.

CONFLICTS OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. McDermott P (2009) Painful bladder syndrome/interstitial cystitis (history, epidemiology, symptoms, diagnosis and treatments). Int J Urol Nurs 3, 16-23
2. Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ and Clemens JQ (2013) The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. J Urol 189, 141-145
3. Clemens JQ, Clauw DJ, Kreder K et al (2015) Comparison of baseline urological symptoms in men and women in the MAPP research cohort. J Urol 193, 1554-1558
4. Kim A, Han JY, Ryu CM et al (2017) Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. Histopathology 71, 415-424
5. Bo K, Frawley HC, Haylen BT et al (2017) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Int Urogynecol J 28, 191-213
6. Ogawa T, Ishizuka O, Ueda T, Tyagi P, Chancellor MB and Yoshimura N (2015) Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert

http://bmbreports.org
Ahmed Abdal Dayem, Extracellular vesicles from stem cells for intestinal cystitis/bladder pain syndrome

10. Wu XR, Kong XP, Pellicer A, Kreibich G and Sun TT (2009) Uroplakins in urothelial biology, function, and disease. Kidney Int 75, 1133-1166

16. Abdal Dayem A, Kim K, Lee SB, Kim A and Cho SG (2020) A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration. Dev Dyn 243, 988-998

34. Kim H-J (2016) Update on the pathology and diagnosis of interstitial cystitis/bladder pain syndrome: methods and perspectives. J Clin Med 9, 766

35. McLennan MT (2014) Interstitial cystitis: epidemiology, current and future perspectives. TheScientificWorldJOURNAL 11, 1479-1488

36. Lewis SA (2000) Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 278, F67-F874

37. Neuhaus J, Heinrich M, Schlichting N et al (2007) Structure and function of suburothelial myofibroblasts in the human urinary bladder under normal and pathological conditions. Der Urologe Ausg A 46, 1197-1202

38. Parsons CL (2011) The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int 107, 370-375

39. Birder L and Andersson K-E (2013) Urothelial signaling. Physiol Rev 93, 653-680

40. Lopez SR and Mangr N (2021) Current standard of care in treatment of bladder pain syndrome/interstitial cystitis. Ther Adv Urol 13, 1756287221022478

41. Warren JW, Brown V, Jacobs S, Horne L, Langenberg P and Greenberg P (2008) Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology 71, 1085-1090
42. Shea-Donohue T, Stiltz J, Zhao A and Notari L (2010) Mast cells. Curr Gastroenterol Rep 12, 349-357
43. Gamper M, Regauer S, Welter J, Eberhard J and Viereck V (2015) Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? Urol 193, 1994-2000
44. Van De Merwe JP (2007) Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol 4, 484-491
45. Lee C-K, Tsai CP, Liao TL et al (2019) Overactive bladder and bladder pain syndrome/interstitial cystitis in primary Sjögren’s syndrome patients: a nationwide population-based study. PLoS One 14, e0225455
46. Phinney DG and Wittenger MF (2017) Concise review: msc-derived exosomes for cell-free therapy. Stem Cells 35, 851-858
47. Wu S, Cheng Z, Liu G et al (2013) Urothelial differentiation of human umbilical cord-derived mesenchymal stromal cells in vitro. Anal Cell Pathol 36, 63-69
48. Song B, Jiang W, Alraies A et al (2016) Bladder smooth muscle cells differentiation from dental pulp stem cells: future potential for bladder tissue engineering. Stem Cells Int 2016, 6979368
49. Jiang W, Wang D, Alraies A et al (2019) Wnt-GSK3β/Catenin regulates the differentiation of dental pulp stem cells into bladder smooth muscle cells. Stem cells international 2019
50. Kim A, Shin DM and Choo MS (2016) Stem cell therapy for interstitial cystitis/bladder pain syndrome. Curr Urol Rep 17, 1-9
51. Kuriyan AE, Albini TA, Townsend JH et al (2017) Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med 376, 1047-1053
52. Barkholt L, Flory E, Jekerle V et al (2013) Risk of tumorigenicity in mesenchymal stromal cell-based therapies—bridging scientific observations and regulatory viewpoints. Cytotherapy 15, 753-759
53. Herberts CA, Kwa MS and Hermsen HP (2011) Risk factors in the development of stem cell therapy. J Transl Med 9, 1-14
54. Musial-Wysoka A, Kot M and Majka M (2019) The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant 28, 801-812
55. Kraitzman DL, Tatsumi M, Gilson WD et al (2005) Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112, 1451-1461
56. McBride C, Gaupp D and Phinney D (2003) Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by realtime PCR. Cytotherapy 5, 7-18
57. François S, Bensidhoum M, Mouiseddine M et al (2006) Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem cells 24, 1020-1029
58. Toma C, Wagner WR, Bowry S, Schwartz A and Villanueva F (2009) Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res 104, 398-402
59. Wei W, Ao Q, Wang X et al (2021) Mesenchymal stem cell-derived exosomes: a promising biological tool in nanomedicine. Front Pharmacol 11, 590470
60. Kuret T, Peskar D, Erman A and Veranić P (2021) A systematic review of therapeutic approaches used in experimental models of interstitial cystitis/bladder pain syndrome. Biomedicines 9, 865
61. da Silva Meirelles L, Caplan AI and Nardi NB (2008) In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26, 2287-2299
62. Caplan AI and Correa D (2011) The MSC: an injury drugstore. Cell Stem Cell 9, 11-15
63. Gneccchi M, He H, Liang OD et al (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11, 367-368
64. Goolaerts A, Pelland-Randriajaranon N, Langhero J et al (2014) Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. Am J Physiol - Lung Cell Mol Physiol 306, L975-L985
65. Tremain N, Korkko J, Ibberson D, Kopen GC, DiGirolamo P and Phinney DG (2001) MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells 19, 408-418
66. Ren J, Jin P, Sabatino M et al (2011) Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy 13, 661-674
67. Tian H, Bharadwaj S, Liu Y et al (2010) Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering. Biomaterials 31, 870-877
68. Sharma AK, Hota PV, Matoka DJ et al (2010) Urinary bladder smooth muscle regeneration utilizing bone marrow derived mesenchymal stem cell seeded elastomeric poly (1, 8-octanediol-co-citrate) based thin films. Biomaterials 31, 6207-6217
69. Zhang Y, Lin HK, Frimberger D, Epstein RB and Kropp BP (2005) Growth of bone marrow stromal cells on small intestinal submucosa: an alternative cell source for tissue engineered bladder. BJU Int 96, 1120-1125
70. Ohishi M and Schipani E (2010) Bone marrow mesenchymal stem cells. J Cell Biochem 109, 277-282
71. Yu B, Kim HW, Gong M et al (2015) Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int J Cardiol 182, 349-360
72. Mendt M, Rezvani K and Shpall E (2019) Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant 54, 789-792
73. Wen C, Xie L and Hu C (2022) Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome. J Cell Mol Med 26, 624-635
74. Parekkadan B and Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12, 87-117
75. Kang H, Kim J and Park J (2017) Methods to isolate extracellular vesicles for diagnosis. Micro Nano Syst Lett 5, 15
76. Zhao Z, Wijerathne H, Godwin AK and Soper SA (2021) Isolation and analysis methods of extracellular vesicles (EVs). Extracellular Vesicles Circ Nuc Acids 2, 80-103
77. Théry C, Witwer KW, Akawa E et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018)
Extracellular vesicles from stem cells for intestinal cystitis/bladder pain syndrome
Ahmed Abdal Dayem, et al.

2018; a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7, 1535750
78. Ludwig N, Whiteside TL and Reichert TE (2019) Challenges in exosome isolation and analysis in health and disease. Int J Mol Sci 20, 4684
79. Harding C, Heuser J and Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97, 329-339
80. Cocucci E and Meldolesi J (2015) Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol 25, 364-372
81. Lai RC, Yeo RW and Lim SK (2015) Mesenchymal stem cell exosomes. Semin Cell Dev Biol 40, 82-88
82. Giebel B, Kordelas L and Börger V (2017) Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles. Stem Cell Invest 4, 84
83. Yeo RWY and Lim SK (2016) Exosomes and their therapeutic applications. ADVANCES IN PHARMACEUTICAL CELL THERAPY: Principles of Cell-Based Biopharmaceuticals 477-501
84. Toh WS, Lai RC, Hui JHP and Lim SK (2017) MSC exosome as a cell-free MSC therapy for cartilage regeneration: implications for osteoarthritis treatment. Semin Cell Dev Biol 67, 56-64
85. Zhang S, Chuah SJ, Lai RC, Hui JHP, Lim SK and Toh WS (2018) MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials 156, 16-27
86. Hu S, Wang X, Li Z et al (2021) Platelet membrane and stem cell exosome hybrids enhance cellular uptake and targeting to heart injury. Nano Today 39, 101210
87. Popowski KD, Dinh PUC, George A, Lutz H and Cheng K (2021) Exosome therapeutics for COVID-19 and respiratory viruses. View (Beijing) 2, 20200186
88. Gonzalez-King H, Garcia NA, Ontoria-Oviedo I, Ciria M, Montero JA and Sepúlveda P (2017) Hypoxia inducible factor-1α potentiates jagged 1 mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cells 35, 1747-1759
89. Anderson JD, Johansson HI, Graham CS et al (2016) Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cells 34, 601-613
90. Adamowicz J, Pokrywczynska M and Drewa T (2014) Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitialis. Med Hypotheses 82, 670-673
91. Xie J, Liu B, Chen J et al (2018) Umbilical cord-derived mesenchymal stem cells alleviated inflammation and inhibited apoptosis in interstitial cystitis via AKT/mTOR signaling pathway. Biochem Biophys Res Commun 495, 546-552
92. Wiafe B, Adesida A, Churchhill T, Adewuyi EE, Li Z and Metcalfe P (2017) Hypoxia-increased expression of genes involved in inflammation, dedifferentiation, pro-fibrosis, and extracellular matrix remodeling of human bladder smooth muscle cells. In Vitro Cell Dev Biol Anim 53, 58-66
93. Wiafe B, Adesida A, Churchhill T and Metcalfe P (2018) Mesenchymal stem cells inhibit hypoxia-induced inflammatory and fibrotic pathways in bladder smooth muscle cells. World J Urol 36, 1157-1165
94. Ly JW, Wen W, Jiang C et al (2017) Inhibition of microRNA-214 promotes epithelial-mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2. Exp Mol Med 49, e357-e357
95. Wang Y, Zhao R, Liu D et al (2018) Exosomes derived from miR-214-enriched bone marrow-derived mesenchymal stem cells regulate oxidative damage in cardiac stem cells by targeting CaMKII. Oxid Med Cell Longev 2018, 4971261
96. Yang C, Lim W, Park J, Park S, You S and Song G (2019) Anti-inflammatory effects of mesenchymal stem cell-derived exosomal microRNA-146a-5p and microRNA-548e-5p on human trophoblast cells. Mol Hum Reprod 25, 755-771
97. Li Y, Zhang J, Shi J et al (2021) Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis. Stem Cell Res Ther 12, 221
98. Xie L and Zeng Y (2020) Therapeutic potential of exosomes in pulmonary fibrosis. Front pharmacol 11, 590972-590972
99. Tavasolian F, Hosseini AZ, Souli S and Naderi M (2020) miRNA-146a improves immunomodulatory effects of MSC-derived exosomes in rheumatoid arthritis. Curr Gene Ther 20, 297-312